The Tectonic Shift: De-Risking From China
The global economy is undergoing the largest supply chain realignment since World War II. Between 2020-2024, over $200 billion in manufacturing investments announced for India. Apple alone committed $40 billion of India production by 2025 (up from $7 billion in 2023). Samsung, Foxconn, Wistron, Flex, Pegatron—every major electronics manufacturer is building India capacity at scale.
This isn't 'diversification.' This is de-risking from a single point of catastrophic failure: China. And the critical insight for investors: This manufacturing shift creates demand for deep tech infrastructure that doesn't exist yet in India. That's the opportunity.
What's Driving the Shift?
Geopolitical Risk (Taiwan Strait): If China invades Taiwan, the global semiconductor supply chain collapses overnight. TSMC produces 60% of the world's chips and 90% of advanced chips. There is no Plan B. Companies are finally pricing in this tail risk.
US-China Trade War: US tariffs on Chinese goods now average 20% (up from 3% in 2017). Export controls on advanced chips, AI hardware, and quantum technology make China a less reliable partner. Apple can't risk Chinese retaliation shutting down iPhone production.
COVID-19 Supply Chain Shock: The pandemic revealed catastrophic single-source dependency. China's Rising Costs: Chinese labor costs have risen 5X since 2000—the 'cheap China manufacturing' arbitrage is gone.
Western Consumer Sentiment: Growing anti-China sentiment in US/Europe. Brands want to say 'Made in India,' not 'Made in China.' Apple marketing now highlights India manufacturing.
The Numbers: How Much is Actually Moving?
Electronics & Semiconductors ($150B+): Apple via Foxconn, Wistron, Pegatron at $40B. Samsung $10B in Noida. Foxconn $20B across multiple factories. Micron $2.75B semiconductor facility. Tata Electronics $11B semiconductor fab.
Automobiles & EVs ($80B+): Hyundai, Kia, MG Motors $10B+ combined expansion. VinFast $2B EV manufacturing. Auto component ecosystem $50B+.
Pharmaceuticals & Medical Devices ($30B+): Pfizer, Merck, Abbott $5B+ combined expansion. Indian pharma $15B capex. Medical device manufacturing $10B.
Aerospace & Defense ($40B+): Boeing $5B offset obligations. Airbus $3B component manufacturing. Lockheed Martin, Raytheon, BAE Systems $10B+. Total Announced (2020-2025): $350 Billion USD with estimates of $500B to $1 Trillion over next decade.
Why India? The Honest Assessment
India's Advantages: 1.4 billion person market (Apple India revenue $8B+ growing 50% YoY), 1.5 million engineers annually (Vietnam produces 50,000), established manufacturing ecosystem (automotive, pharma), most aggressive PLI schemes globally (15-20% of production value), and democracy with rule of law for IP protection.
India's Disadvantages: Infrastructure still behind China by 10-15 years (but improving fast), ease of doing business still bureaucratic, higher logistics costs, and component ecosystem still immature (80% component localization targeted by 2028 vs. 20% today).
Bottom line: India won't replace China entirely. But for 30-40% of production (especially where R&D + market access matters), India is the best bet globally.
The Deep Tech Opportunity: Infrastructure for Global Manufacturing
Global manufacturers need Indian deep tech infrastructure that doesn't exist yet. Automation & Robotics: Foxconn needs automation but India has only 3 robots per 10,000 workers (vs. China's 322). Quality Inspection & Testing: Apple's 0.01% defect rate requires AI-powered quality control.
Component Localization: Apple imports ₹2,000+ Cr of components per iPhone—government wants 80% localization. Supply Chain Digitization: Managing 500+ suppliers needs real-time tracking. Green Manufacturing: Apple's carbon-neutral 2030 target requires Indian clean energy solutions.
These companies have ₹10-50 Cr TAM just from existing Apple/Samsung supply chain in India. Add exports, and TAMs are ₹100-500 Cr+.
Why This is a 'Why Now' Moment
The China+1 shift is happening now (2020-2030 window). Companies are making factory location decisions now. Once a $5B fab is built in Vietnam, it's locked in for 20 years. PLI schemes expire 2026-2030. The 'land grab' period is now.
Early-stage deep tech companies (TRL 4-5) founded 2022-2024 will hit commercial scale by 2026-2028—exactly when global manufacturers need Indian suppliers at scale.
We're investing in companies building the picks and shovels for India's manufacturing gold rush. Why now? Because the China+1 shift is creating $400B of demand for Indian deep tech infrastructure over the next 5-10 years.